A Phase II Open Label Single Arm Study of Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT)
Phase of Trial: Phase II
Latest Information Update: 18 May 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Bladder cancer; Ureteral-neoplasms; Urethral cancer
- Focus Therapeutic Use
- Acronyms NEXT
- 20 Jul 2017 Status changed from not yet recruiting to recruiting.
- 06 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jul 2017.
- 02 Jun 2017 New trial record